Parallel Bio, a biotechnology company, has developed “Clinical Trial in a Dish,” a revolutionary platform that employs human models for testing immunotherapies. This system utilizes immune organoids, miniature organs replicating the human immune system, to assess drug safety and efficacy at earlier stages of drug discovery.
Unlike traditional animal testing, which often fails to predict human responses accurately, Clinical Trial in a Dish models represent the biology and diversity of actual patient populations. By harnessing organoid technology, Parallel Bio can mimic human organs’ structure, function, and response to disease and treatment.
Five pharmaceutical companies, including a Fortune 500 firm, have adopted the platform, which is testing over 20 drug candidates. Tests conducted by Parallel Bio have demonstrated a high correlation between Clinical Trial in a Dish results and subsequent clinical data, indicating its potential to significantly improve drug discovery success rates.
This innovative platform promises to revolutionize drug development by bridging the gap between preclinical and clinical trials. By identifying safe and effective drug candidates in humans from the outset, Clinical Trial in a Dish aims to reduce drug development time and costs, ultimately leading to more patient cures.
Key benefits of Clinical Trial in a Dish include:
• Patient-specific models that represent the diversity of the human population
• Scalability through robotics for high-throughput testing
• Accurate prediction of drug safety and efficacy, reducing risk in human trials
• Cost-effectiveness and time savings compared to traditional animal studies
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.